Literature DB >> 7916513

Site-directed mutagenic analysis of reovirus sigma 3 protein binding to dsRNA.

K L Denzler1, B L Jacobs.   

Abstract

The S4 gene of reovirus encodes a double-stranded RNA-binding protein, sigma 3, that can inhibit activation of the interferon-induced dsRNA-dependent protein kinase, PKR. In this study, we attempted to localize the region of sigma 3 involved in dsRNA-binding by constructing deletion and point mutations, expressing the mutated proteins in COS cells, and testing the ability of the native mutated proteins to bind dsRNA-agarose. Transfection of S4 into COS cells resulted in expression of two forms of sigma 3, a full-length protein, and a protein containing a small truncation at the amino-terminal end. The truncation is likely due to a proteolytic event. Deletions of as few as 10 amino acids from the amino-terminal end of the protein or 10 amino acids from the carboxyl-terminal end of the protein resulted in loss of dsRNA-binding activity. A putative dsRNA-binding domain has previously been localized to an 85 amino acid region located between amino acids 234 and 297 (Miller, J. E., and Samuel, C. E., J. Virol. 66, 5347-5356 1992). Mutagenesis of basic residues located within two distinct motifs of this region showed that some basic residues are absolutely required for binding to dsRNA while others can be changed with little effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916513     DOI: 10.1006/viro.1994.1523

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

1.  Structure of the reovirus outer capsid and dsRNA-binding protein sigma3 at 1.8 A resolution.

Authors:  A M Olland; J Jané-Valbuena; L A Schiff; M L Nibert; S C Harrison
Journal:  EMBO J       Date:  2001-03-01       Impact factor: 11.598

2.  Longer and shorter forms of Sendai virus C proteins play different roles in modulating the cellular antiviral response.

Authors:  D Garcin; J Curran; M Itoh; D Kolakofsky
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response.

Authors:  Robert H Silverman
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

4.  Possible involvement of the double-stranded RNA-binding core protein sigmaA in the resistance of avian reovirus to interferon.

Authors:  J Martínez-Costas; C González-López; V N Vakharia; J Benavente
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Reovirus outer capsid protein micro1 induces apoptosis and associates with lipid droplets, endoplasmic reticulum, and mitochondria.

Authors:  Caroline M Coffey; Alexander Sheh; Irene S Kim; Kartik Chandran; Max L Nibert; John S L Parker
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Nonstructural Protein σ1s Is Required for Optimal Reovirus Protein Expression.

Authors:  Matthew B Phillips; Johnasha D Stuart; Emily J Simon; Karl W Boehme
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

7.  Regulated, stable expression and nuclear presence of reovirus double-stranded RNA-binding protein sigma3 in HeLa cells.

Authors:  Z Yue; A J Shatkin
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Mutations in the zinc-binding motif of the reovirus capsid protein delta 3 eliminate its ability to associate with capsid protein mu 1.

Authors:  D A Shepard; J G Ehnstrom; P J Skinner; L A Schiff
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency In Vitro and In Vivo.

Authors:  Adil Mohamed; Derek R Clements; Shashi A Gujar; Patrick W Lee; James R Smiley; Maya Shmulevitz
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

10.  Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination.

Authors:  Sangeetha Vijaysri; Garilyn Jentarra; Michael C Heck; Andrew A Mercer; Colin J McInnes; Bertram L Jacobs
Journal:  Vaccine       Date:  2007-12-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.